Cavidi AB is making significant strides in enhancing the capabilities of immunoassays, a cornerstone technique in diagnostics and biomedical research, through its innovative BOLD signal amplification technology. This advancement, detailed by Principal Scientist Peter Stenlund, promises to overcome long-standing limitations in detecting low-abundance biomarkers and accurately quantifying critical analytes, thereby offering profound implications for early disease detection, pharmacokinetic studies, and personalized medicine. Stenlund, a distinguished protein chemist with a Ph.D. in biochemistry from Umeå University (Sweden), brings extensive expertise from roles at Biacore, Octapharma, and Galderma, making him a pivotal figure in Cavidi’s pursuit of ultra-sensitive immunoassay solutions. His leadership in developing technologies like BOLD (Biomarker Optimized Ligation Detection) is poised to redefine the landscape of high-performance analytical methods.
The Crucial Need for Enhanced Immunoassay Sensitivity
Immunoassays, particularly the Enzyme-Linked Immunosorbent Assay (ELISA), are indispensable tools for detecting and quantifying proteins, peptides, and other biomolecules in complex biological samples. They are widely used in clinical diagnostics for disease markers, in drug development for pharmacokinetic (PK) and pharmacodynamic (PD) studies, and in basic research. However, traditional immunoassays often face a critical challenge: a lack of sufficient sensitivity to detect analytes present at very low concentrations, which are often indicative of early-stage diseases or subtle physiological changes. This limitation can hinder early diagnosis, prevent precise monitoring of therapeutic responses, and obscure the detection of novel, low-abundance biomarkers. The demand for more sensitive, robust, and reproducible assays has been a persistent driver of innovation in the field. Cavidi AB’s BOLD technology emerges as a direct response to this unmet need, aiming to significantly boost signal detection without compromising assay integrity or ease of use.
Navigating the Sensitivity Paradox: ULOQ and Clinical Relevance
A common concern with increasing assay sensitivity is the potential for misinterpretation of data, particularly the detection of physiological or baseline levels that might not represent clinically significant thresholds. Peter Stenlund elaborates on this paradox, confirming that while increased sensitivity inherently allows for the detection of lower concentrations, it also impacts the assay’s upper limit of quantification (ULOQ). With BOLD amplification, a lower analyte concentration generates a higher signal, which means the ULOQ will typically shift downwards. The precise extent of this shift is dependent on the dynamic range and saturation characteristics of the instrument and detector used. Conversely, the enhanced sensitivity concurrently results in a significantly lower lower limit of quantification (LLOQ), expanding the detection window at the critical low end.
Stenlund provided a compelling example involving Interleukin-4 (IL-4), a cytokine crucial in immune responses. In a side-by-side comparison of a standard IL-4 ELISA and a BOLD-amplified Exazym® Human IL-4 ELISA, the BOLD/Exazym® assay demonstrated earlier signal saturation, leading to a lower apparent ULOQ compared to its standard counterpart. This visual evidence underscores the BOLD technology’s profound impact on signal intensity. Critically, Stenlund emphasized that this increased sensitivity enables a much-improved characterization of normal baseline levels and biological variability, data points often inaccessible with standard immunoassays. For instances where true clinical concentrations exceed the BOLD-amplified assay’s ULOQ, samples can be readily diluted to fall within the usable dynamic range of the calibration curve, ensuring accurate quantification of even very high, clinically relevant concentrations. This flexibility ensures that the enhanced sensitivity does not restrict the assay’s utility across a broad spectrum of analyte concentrations.
Precision in Bioconjugation: The Role of Click Chemistry
The robust performance of advanced immunoassays hinges on the precise and stable conjugation of detection molecules, such as antibodies, to signaling elements. Cavidi AB employs a sophisticated approach to conjugation, favoring click chemistry over direct conjugation with N-hydroxysuccinimide (NHS)-ester activated oligos. Stenlund clarified that while NHS chemistry is initially utilized to introduce azide groups onto the antibody, direct conjugation with NHS-ester activated oligos is bypassed. This strategic choice is driven by several key advantages.
The additional effort required for the ClickChemN approach is minimal, yet the benefits are substantial. Dibenzocyclooctyl (DBCO)-modified oligos, central to the click chemistry process, have demonstrated remarkable stability as stock reagents. Stenlund highlighted their long-term stability, exceeding two years, a significant improvement over the hydrolysis-sensitive NHS-ester variant of the oligo-dT primer. This enhanced stability of reagents translates directly into more reliable and reproducible assay performance over time. Furthermore, the use of click chemistry for conjugation provides superior control over conjugation stoichiometry. This precise control is paramount for achieving high reproducibility and robustness in the assay. This strategy is well-established and widely adopted in the development of antibody-oligonucleotide conjugates, where controlled and reliable bioconjugation is critical for maintaining the functional integrity of both the antibody and the oligonucleotide.
BOLD vs. Immuno-PCR: A Comparative Analysis
The quest for ultra-sensitive immunoassays has seen the emergence of various technologies, with immuno-PCR (iPCR) being a notable contender. Theoretically, iPCR offers highly improved sensitivity by amplifying the oligonucleotide conjugated to the detection antibody via PCR. However, in practice, iPCR often encounters significant limitations. A primary concern is the inherent risk of contamination, which can lead to false positives and compromise data reliability. Moreover, iPCR necessitates repeated high-temperature cycling, a process that can negatively impact the structural integrity of both the antibody and the antigen, particularly if they are peptides or proteins. Such thermal denaturation can weaken the antibody-antigen binding affinity, thereby counteracting the sensitivity gains from signal amplification.
BOLD technology, by contrast, addresses these shortcomings through a fundamentally different approach. It leverages low-temperature, isothermal, target-dependent signal amplification. This method avoids the harsh thermal cycling required by iPCR, thereby preserving the structural and functional integrity of the biomolecules involved in the immune reaction. The result is superior signal-to-noise ratios and more robust quantification. A significant practical advantage of BOLD is its adaptability: it can be integrated into virtually any existing immunoassay or ELISA with only minimal modifications. This flexibility makes BOLD a practical and efficient solution for boosting sensitivity without requiring a complete redesign of established assay workflows, offering a streamlined path to enhanced performance for researchers and diagnostic laboratories.
Expanding Applications: Pharmacokinetic (PK) Determination
The precision and sensitivity offered by BOLD technology make it particularly well-suited for pharmacokinetic (PK) determination, especially in scenarios demanding the quantification of very low drug concentrations. PK studies are critical in drug development to understand how a drug is absorbed, distributed, metabolized, and excreted by the body. Accurate measurement of drug levels, often in the picogram or femtogram range, is essential for determining dosing regimens, assessing bioavailability, and evaluating drug efficacy and safety.
Stenlund affirmed that BOLD can be effectively applied to immunoassays used for PK determination. Its seamless integration into existing ELISA platforms with minor modifications means it fits comfortably within established PK workflows. The main challenges associated with applying BOLD in PK assays are largely shared with any highly sensitive PK assay, rather than being unique to BOLD itself. These include controlling background noise, ensuring specificity in complex biological matrices like serum or plasma, and managing potential matrix effects. These challenges are routinely addressed through meticulous assay optimization, careful selection of appropriate calibration ranges, and strategic sample dilution when necessary. BOLD’s ability to provide reliable quantification at exceptionally low concentrations makes it an invaluable tool for characterizing the pharmacokinetics of novel therapeutics, particularly biologics and gene therapies, where minute concentrations can have significant clinical implications.
Ensuring Assay Reliability: Reagent Preparation and Maintenance
The performance and reproducibility of any analytical assay are heavily dependent on the quality and stability of its critical reagents. Addressing concerns about reagent preparation and maintenance, Peter Stenlund stated that Cavidi AB has not encountered major challenges in this regard. The company ensures the reliability of its Exazym® kit system by rigorously performance-testing and qualifying all key components, including reagents for antibody conjugation, polymerization, and signal detection. Their functionality is continuously monitored through comprehensive stability and performance studies, guaranteeing that customers receive consistently reliable and well-functioning products.
For the Exazym® critical oligo-dT detector conjugate, which users prepare to link their existing ELISA to BOLD signal amplification, Cavidi AB provides clear recommendations. Depending on the stability profile of the detector antibody, it is advised to add an appropriate preservative and store the conjugate in DNase/RNase-free vials. When these user-prepared reagents are handled according to standard best practices, they exhibit good stability and are well-suited for routine laboratory use. This emphasis on robust quality control and clear user guidelines underscores Cavidi AB’s commitment to ensuring the practical applicability and long-term reliability of its BOLD technology.
Broader Impact and Future Outlook
The introduction of Cavidi AB’s BOLD technology marks a significant advancement in immunoassay capabilities, extending far beyond the immediate technical improvements. Its enhanced sensitivity opens new avenues for early disease detection, particularly for conditions where biomarkers are present at exceedingly low concentrations in initial stages, such as certain cancers, neurodegenerative diseases, and infectious diseases. This could translate into earlier intervention and improved patient outcomes.
In drug discovery and development, BOLD offers unparalleled precision for pharmacokinetic and pharmacodynamic studies, enabling a more granular understanding of drug behavior at low doses and in complex biological systems. This is particularly crucial for the development of biologics, cell, and gene therapies, where precise quantification of therapeutic agents and their effects is paramount. Furthermore, the technology’s ability to characterize normal baseline levels and biological variability with greater accuracy can facilitate the discovery and validation of novel biomarkers, potentially accelerating personalized medicine initiatives.
The practical advantages of BOLD—its isothermal operation, low contamination risk compared to iPCR, and minimal modification requirement for existing ELISAs—position it as a highly adaptable and accessible solution for a broad range of research and clinical laboratories. By providing a robust, reproducible, and user-friendly platform for ultra-sensitive quantification, Cavidi AB is not only addressing current analytical challenges but also laying the groundwork for future breakthroughs in diagnostics, therapeutics, and fundamental biological research. The ongoing development and refinement of such technologies are crucial for pushing the boundaries of what is detectable and quantifiable in biological systems, ultimately benefiting human health and scientific understanding.
To access the full on-demand webinar, further details on the BOLD technology and its applications are available for interested professionals.
Disclaimer
The opinions expressed in this interview are those of the interviewee and do not necessarily reflect the views of BioTechniques or Taylor & Francis Group.
In association with Cavidi.
Leave a Reply